FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

 

 

 

Our liquid biopsy comprehensive genomic profiling service for patients with solid tumours.1,2
  

Single blood draw Two tubes of 8.5 mL peripheral whole blood 3 Clear, in-depth report Incorporates results from prior Foundation Medicine testing 4 Supports your clinical decision-making 4 Complements FoundationOne®CDx Where tissue biopsy is not feasible or is 2 At disease progression 2 Analyses 70 genes and reports MSI-High Detects the four main classes of genomic alterations* in 70 genes 1 Reports MSI-High status 1
Clinical uses

Opens up opportunities with a single blood draw

FoundationOne Liquid extends the benefits of comprehensive genomic profiling to more clinical situations with a single blood draw. Use FoundationOne CDx where tissue is available. When tissue biopsy is not feasible, there is insufficient tissue for analysis and/or when disease progression is suspected, try FoundationOne Liquid.1,2
Solid   tumour p a tient Tissue  b iop s y not f easible Tissue  b iop s y f easible T r e a tment Disease p r og r e s sion suspec t ed Single blood d r a w
Genes and biomarkers

Analyses 70 genes and reports MSI-High status

FoundationOne Liquid leverages the comprehensive genomic profiling approach and, in a single test, detects the four main classes of genomic alterations in 70 genes and reports MSI-High status.1 High specificity and sensitivity ensure you can be confident in the alterations reported.1
MSI Base substitutions Insertions and deletions Copy number alterations Microsatellite instability Rearrangements Analyses70known cancer-relevant genes

ctDNA

Examines circulating tumour DNA (ctDNA)

Cancer patients’ blood contains circulating cell-free DNA (cfDNA) released from healthy tissue and also tumour tissue (ctDNA). This DNA is highly fragmented, in very low amounts and varies between tumour type and patients. FoundationOne Liquid utilises enhanced ctDNA extraction to accurately identify unique ctDNA fragments from a single blood draw.
Tumour Tissue Apoptosis Necrosis Secretion Healthy Tissue Main source of cell-free DNA Apoptosis Release ctDNA Release cell-free DNA
In-depth report

Supports clinical decision-making

A clear, in-depth report provides insights on your patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials. The report incorporates results from prior Foundation Medicine services to provide an integrated view of tumour evolution.4
Lung A denoca r cinoma TU M OR TYP E Sample, Jane P A T I EN T RE P O R T D A T E 0 1 Jan 2 0 18 X X X X X X X X CRF # F o u n d a t i o n A CT® is a n e xt g e n e r a t io n s e q ue n ci n g ( N GS) a s s a y t h a t i d e n t i es c lin i cal l y r e l e v a n t g e n o m i c al t e r a t io n s in ci r c u l a t i n g t u m o r D N A. ABOUT THE TE S T P A TIENT SEX Not Gi v en MEDICAL R E C ORD # Not Gi v en D A TE OF BI R TH Not Gi v en DISEASE Lung A denoca r cinoma NAME Not Gi v en PH Y SICIAN ORDERING PHYSICIAN Not Given PATHOLOGIST Not Given MEDICAL FACILITY ID Not Given MEDICAL FACILITY Not Given ADDITIONAL RECIPIENT Not Given SP E CIMEN DATE OF COLLECTION Not Given SPECIMEN RECEIVED Not Given SPECIMEN ID Not Given SPECIMEN TYPE Blood 0 . 20% e x on 19 deletion (L 7 4 7_A 7 50> P ) E GFR Afatinib Erlotinib Gefitinib Osimertinib Cetuximab Lapatinib Panitumumab see p . 8 10 Trials EGFR exon 19 deletion (L747_A750>P) TP53 C242G F o r a c o m p l e t e li s t o f t h e g e n e s a s s a y e d , p l e a s e r e f e r t o t h e A p p e n di x . G e n o m i c F i n di n g s B io ma r k e r F i n di n g s No reportable biomarker findings were detected. C linical T rials 10 T he r apies with Lack of R esponse 0 T he r apies with C linical Benefit 7 F o r m o r e i n f o rmat i o n r e g a r d i ng bi o l o g i c al a n d c l i n i c al signi c a n c e , i n c l u d i ng p r o g n o s t i c , di a g n o s t i c , g e rml i n e , a n d p o t e ntial c h e m o se nsiti v i i m p l i c at io n s , s e e t h e G e n o m i c F i n d i ngs s e ct i o n. GE N E A L TER A TION S W ITH N O RE P O R T A BLE THER AP EUTIC OR CLI N I C A L TR IA L S O P TION S p . 3 C 2 4 2 G T P 5 3 Genomic al t e r a tions de t e c t ed m a y be a s s oci a t ed with a c tivi t y o f c e r tain F D A - app r o v ed drugs; h o w e v e r , the a g en t s li s t ed in this r epo r t m a y h a v e v aried clinical e viden c e in the p a tient s tumor t ype. Neither the the r apeutic a g en t s nor the trials identified a r e r an k ed in o r der o f p o t ential or p r edi c t ed e ffica c y f or this p a tient, nor a r e th e y r an k ed in o r der o f l e v el o f e viden c e f or this p a tient s tumor t ype. In the app r opri a t e clinical c on t e x t, g ermline t e s ting o f A P C , B R C A1, B R C A2, CDH1, NF1, P ALB2, RB1, RE T , S TK11, and TP 5 3 is r e c ommended. N / A= N o t Applicable; Mutant Allele F r equen c y is n o t applicable f or c o p y number amplific a tions or r e ar r an g emen t s. N O TE Ele c t r onically Signed b y Julia A . Elvin, M. D ., Ph. D . • J e ff r e y S . R o s s, M. D ., Medical Di r e c t or • 30 N o v ember 2 0 17 F ound a tion Medicine, Inc. • 1-888 - 9 88 - 3 6 39 S ample P r e p a r a tion: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 S ample Anal y sis: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 o f P A GE A CTIO NA BIL I T Y BIOM AR KER FI N DI N G S There are no Biomarker Findings for this sample THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE) THERAPIES WITH CLINICAL BENEFIT (IN PATIENT’S TUMOR TYPE) GE N OMIC FI N DI N G S MAF % F oundationOneLiquid ® is a n e xt g ene r ation sequencing (NGS) a s s a y that identifies clinically r el ev ant g enomic al t e r ations in ci r culating tumor DNA. Lung A denoca r cinoma TU M OR TYP E Sample, Jane P A T I EN T RE P O R T D A T E 0 1 Jan 2 0 18 X X X X X X X X CRF # F o u n d a t i o n A CT® is a n e xt g e n e r a t io n s e q ue n ci n g ( N GS) a s s a y t h a t i d e n t i es c lin i cal l y r e l e v a n t g e n o m i c al t e r a t io n s in ci r c u l a t i n g t u m o r D N A. ABOUT THE TE S T P A TIENT SEX Not Gi v en MEDICAL R E C ORD # Not Gi v en D A TE OF BI R TH Not Gi v en DISEASE Lung A denoca r cinoma NAME Not Gi v en PH Y SICIAN ORDERING PHYSICIAN Not Given PATHOLOGIST Not Given MEDICAL FACILITY ID Not Given MEDICAL FACILITY Not Given ADDITIONAL RECIPIENT Not Given SP E CIMEN DATE OF COLLECTION Not Given SPECIMEN RECEIVED Not Given SPECIMEN ID Not Given SPECIMEN TYPE Blood 0 . 20% e x on 19 deletion (L 7 4 7_A 7 50> P ) E GFR Afatinib Erlotinib Gefitinib Osimertinib Cetuximab Lapatinib Panitumumab see p . 8 10 Trials EGFR exon 19 deletion (L747_A750>P) TP53 C242G F o r a c o m p l e t e li s t o f t h e g e n e s a s s a y e d , p l e a s e r e f e r t o t h e A p p e n di x . G e n o m i c F i n di n g s B io ma r k e r F i n di n g s No reportable biomarker findings were detected. C linical T rials 10 T he r apies with Lack of R esponse 0 T he r apies with C linical Benefit 7 F o r m o r e i n f o rmat i o n r e g a r d i ng bi o l o g i c al a n d c l i n i c al signi c a n c e , i n c l u d i ng p r o g n o s t i c , di a g n o s t i c , g e rml i n e , a n d p o t e ntial c h e m o se nsiti v i i m p l i c at io n s , s e e t h e G e n o m i c F i n d i ngs s e ct i o n. GE N E A L TER A TION S W ITH N O RE P O R T A BLE THER AP EUTIC OR CLI N I C A L TR IA L S O P TION S p . 3 C 2 4 2 G T P 5 3 Genomic al t e r a tions de t e c t ed m a y be a s s oci a t ed with a c tivi t y o f c e r tain F D A - app r o v ed drugs; h o w e v e r , the a g en t s li s t ed in this r epo r t m a y h a v e v aried clinical e viden c e in the p a tient s tumor t ype. Neither the the r apeutic a g en t s nor the trials identified a r e r an k ed in o r der o f p o t ential or p r edi c t ed e ffica c y f or this p a tient, nor a r e th e y r an k ed in o r der o f l e v el o f e viden c e f or this p a tient s tumor t ype. In the app r opri a t e clinical c on t e x t, g ermline t e s ting o f A P C , B R C A1, B R C A2, CDH1, NF1, P ALB2, RB1, RE T , S TK11, and TP 5 3 is r e c ommended. N / A= N o t Applicable; Mutant Allele F r equen c y is n o t applicable f or c o p y number amplific a tions or r e ar r an g emen t s. N O TE Ele c t r onically Signed b y Julia A . Elvin, M. D ., Ph. D . • J e ff r e y S . R o s s, M. D ., Medical Di r e c t or • 30 N o v ember 2 0 17 F ound a tion Medicine, Inc. • 1-888 - 9 88 - 3 6 39 S ample P r e p a r a tion: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 S ample Anal y sis: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 o f P A GE A CTIO NA BIL I T Y BIOM AR KER FI N DI N G S There are no Biomarker Findings for this sample THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE) THERAPIES WITH CLINICAL BENEFIT (IN PATIENT’S TUMOR TYPE) GE N OMIC FI N DI N G S MAF % F oundationOneLiquid ® is a n e xt g ene r ation sequencing (NGS) a s s a y that identifies clinically r el ev ant g enomic al t e r ations in ci r culating tumor DNA. Solid tumor bio p s y 2 5 F eb 2 0 17 Liquid bio p s y 7 Apr 2 0 17 Liquid bio p s y 12 Jun 2 0 17 N o t De t ec t ed Mu t ant Allele F r eq u ency P e r c en t a g e (MAF%) Mic r o s a t elli t e s t a tus de t ec t ed Cann o t Be De t ermined 2 3 . 00% n / a e x on 19 deletion (L 7 4 7_A 7 50> P ) E GFR Cann o t Be De t ermined T umor Mut a tional Bu r den T E S T 1 T E S T 2 MA F % 0 . 20% n / a T E S T 3 MA F % - 2 2.8% N o t T es t ed N o t T es t ed C H AN G E F R O M PR E V . HI S T O R IC P A TIE N T FI N DI N G S 2% 40% Ele c t r onically Signed b y Julia A . Elvin, M. D ., Ph. D . • J e ff r e y S . R o s s, M. D ., Medical Di r e c t or • 30 N o v ember 2 0 17 F ound a tion Medicine, Inc. • 1-888 - 9 88 - 3 6 39 S ample P r e p a r a tion: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 S ample Anal y sis: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 o f P A GE de t ec t ed 12 . 50% C 2 42G TP53 0 . 10% - 12 . 40% Lung A denoca r cinoma TU M OR TYP E Sample, Jane P A T I EN T RE P O R T D A T E 0 1 Jan 2 0 18 X X X X X X X X CRF # Solid tumor bio p s y 2 5 F eb 2 0 17 Liquid bio p s y 7 Apr 2 0 17 Liquid bio p s y 12 Jun 2 0 17 N o t De t ec t ed Mu t ant Allele F r eq u ency P e r c en t a g e (MAF%) Mic r o s a t elli t e s t a tus de t ec t ed Cann o t Be De t ermined 2 3 . 00% n / a e x on 19 deletion (L 7 4 7_A 7 50> P ) E GFR Cann o t Be De t ermined T umor Mut a tional Bu r den T E S T 1 T E S T 2 MA F % 0 . 20% n / a T E S T 3 MA F % - 2 2.8% N o t T es t ed N o t T es t ed C H AN G E F R O M PR E V . HI S T O R IC P A TIE N T FI N DI N G S 2% 40% Ele c t r onically Signed b y Julia A . Elvin, M. D ., Ph. D . • J e ff r e y S . R o s s, M. D ., Medical Di r e c t or • 30 N o v ember 2 0 17 F ound a tion Medicine, Inc. • 1-888 - 9 88 - 3 6 39 S ample P r e p a r a tion: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 S ample Anal y sis: 150 Se c ond S t., 1 s t F loo r , Cambrid g e, MA 0 2 1 4 1 • CLIA: 2 2D2 0 2 7 5 31 o f P A GE de t ec t ed 12 . 50% C 2 42G TP53 0 . 10% - 12 . 40% Lung A denoca r cinoma TU M OR TYP E Sample, Jane P A T I EN T